Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Metropolitan Greatness: The 6 Urban areas for Quality Living in 2024 - 2Rocket shines under the northern lights | Space photo of the day for March 25, 2026
- 3Israeli girl suffers cardiac arrest during sirens in Safed, hospitalized in serious condition
- 4Figure out What Experience Level Means for Medical caretaker Compensation Dealings
- 5Flu cases skyrocket in US. See cases, where people got sick.
- Iran war drives global fertilizer prices up, raising food cost fears
- At 72, Kathie Lee Gifford says aging isn’t what she expected. 'The golden years? It’s a lie.’
- How HIV/AIDS got its name − the words Americans used for the crisis were steeped in science, stigma and religious language
- Mobility exercises are an important part of fitness as we age. Here are some tips
- Arrow Exploration brings new Colombian oil well on stream ahead of schedule and under budget
- Hilary Duff releases 'Mature,' her 1st song in 10 years
- Vote In favor of Your Favored Distributed computing Administration
- How is 'A Knight of the Seven Kingdoms' connected to 'Game of Thrones'?
- The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
